Emcure Pharmaceuticals has completed the acquisition of the remaining 20.42% equity stake in Zuventus Healthcare for ₹7,249 million. This acquisition makes Zuventus a wholly-owned subsidiary of Emcure. The purchase of 4,095,180 equity shares has been completed, with the shares credited to Emcure’s demat account. This move reinforces Emcure’s control over Zuventus and is expected to streamline operations and strategic alignment.
Full Ownership of Zuventus
Emcure Pharmaceuticals has successfully acquired the remaining 20.42% stake in Zuventus Healthcare, solidifying its position as the sole owner. The deal, initially announced on June 21, 2025, has now been finalized with the transfer of shares to Emcure’s account. The total consideration for this acquisition is ₹7,249 million.
Details of the Transaction
The acquisition involved the purchase of 4,095,180 equity shares from individual shareholders. The shares, valued at ₹10 each, represent the remaining portion of Zuventus not already owned by Emcure. With this acquisition, Zuventus Healthcare is now a 100% owned subsidiary of Emcure Pharmaceuticals.
Zuventus Healthcare Overview
Zuventus Healthcare is involved in pharmaceutical medicaments. The company’s financials for the year ended March 31, 2025, show a turnover of ₹10,798.99 million and a profit after tax (PAT) of ₹1,347.82 million. This acquisition will allow Emcure to further integrate Zuventus’s operations and leverage synergies within the group.
Source: BSE
